NasdaqGS - Delayed Quote USD

Guardant Health, Inc. (GH)

27.10 -0.37 (-1.35%)
At close: May 31 at 4:00 PM EDT
27.45 +0.35 (+1.29%)
Pre-Market: 7:00 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
603,725.00
563,948.00
449,538.00
373,653.00
286,730.00
--
Cost of Revenue
239,275.00
227,052.00
156,325.00
122,912.00
92,535.00
--
Gross Profit
364,450.00
336,896.00
293,213.00
250,741.00
194,195.00
--
Operating Expense
894,803.00
901,621.00
837,591.00
661,742.00
449,145.00
--
Operating Income
-530,353.00
-564,725.00
-544,378.00
-411,001.00
-254,950.00
--
Net Non Operating Interest Income Expense
44,594.00
32,787.00
3,492.00
1,353.00
5,405.00
--
Other Income Expense
25,708.00
53,174.00
-112,563.00
25,178.00
3,641.00
--
Pretax Income
-460,051.00
-478,764.00
-653,449.00
-384,470.00
-245,904.00
--
Tax Provision
850.00
685.00
1,139.00
300.00
379.00
--
Net Income Common Stockholders
-460,901.00
-479,449.00
-654,588.00
-405,670.00
-253,783.00
--
Diluted NI Available to Com Stockholders
-460,901.00
-479,449.00
-654,588.00
-405,670.00
-253,783.00
--
Basic EPS
-3.92
-4.28
-6.41
-4.00
-2.60
--
Diluted EPS
-3.92
-4.28
-6.41
-4.00
-2.60
--
Basic Average Shares
116,750.25
111,988.00
102,178.00
101,314.00
97,504.00
--
Diluted Average Shares
116,750.25
111,988.00
102,178.00
101,314.00
97,504.00
--
Total Operating Income as Reported
-530,353.00
-564,725.00
-544,378.00
-411,001.00
-254,950.00
--
Total Expenses
1,134,078.00
1,128,673.00
993,916.00
784,654.00
541,680.00
--
Net Income from Continuing & Discontinued Operation
-460,901.00
-479,449.00
-654,588.00
-405,670.00
-253,783.00
--
Normalized Income
-460,901.00
-479,449.00
-654,588.00
-405,670.00
-253,783.00
--
Interest Income
47,173.00
35,365.00
6,069.00
3,930.00
10,171.00
--
Interest Expense
2,579.00
2,578.00
2,577.00
2,577.00
4,766.00
--
Net Interest Income
44,594.00
32,787.00
3,492.00
1,353.00
5,405.00
--
EBIT
-457,472.00
-476,186.00
-650,872.00
-381,893.00
-241,138.00
--
EBITDA
-414,224.00
-433,305.00
-614,910.00
-359,622.00
-225,073.00
--
Reconciled Cost of Revenue
239,275.00
227,052.00
156,325.00
122,912.00
92,535.00
--
Reconciled Depreciation
43,248.00
42,881.00
35,962.00
22,271.00
16,065.00
--
Net Income from Continuing Operation Net Minority Interest
-460,901.00
-479,449.00
-654,588.00
-405,670.00
-253,783.00
--
Normalized EBITDA
-414,224.00
-433,305.00
-614,910.00
-359,622.00
-225,073.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
12/31/2019 - 10/4/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EXAS Exact Sciences Corporation
45.45
+0.44%
 
NTRA Natera, Inc.
106.56
-3.23%
 
ILMN Illumina, Inc.
104.28
+3.20%
 
TWST Twist Bioscience Corporation
41.88
+2.57%
 
A Agilent Technologies, Inc.
130.41
-0.77%
 
CDNA CareDx, Inc
13.01
-3.77%
 
VCYT Veracyte, Inc.
20.75
-1.14%
 
WAT Waters Corporation
308.90
+0.42%
 
MYNZ Mainz Biomed N.V.
0.8692
+20.39%
 
MEDP Medpace Holdings, Inc.
386.34
+0.17%